Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
Century Therapeutics (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer and autoimmune diseases that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived cell product candidates are designed to specifically target hematologic and solid tumor cancers, with a broadening application to autoimmune diseases. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer and autoimmune disease care. For more information on Century Therapeutics please visit .PHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune disease, today announced that members of the management team will participate in the following events at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024:
費城，2024年11月26日（環球新聞通訊）-- 世紀治療公司（納斯達克：IPSC）是一家創新的生物技術公司，專注於開發基於誘導性多能幹細胞（iPSC）的免疫腫瘤學和自身免疫疾病的細胞治療。今天，公司宣佈管理團隊成員將參與2024年12月4日星期三在派傑投資舉辦的第36屆年醫療會議的以下活動：
-
Autoimmune Disease Cell Therapy Panel: 3:00 PM ET
- Presenter: Chad Cowan, Ph.D., Chief Scientific Officer
-
Fireside Chat: 4:30 PM ET
- Presenters: Brent Pfeiffenberger, Pharm.D., Chief Executive Officer, and Chad Cowan, Ph.D., Chief Scientific Officer
- 自身免疫疾病細胞療法小組：東部時間下午3點
- 演講者：查德·考恩，博士，首席科學官
- 火爐聊天：下午4:30（東部時間）
- 演講者：布倫特·菲芬貝格，藥學博士，首席執行官，查德·考恩，博士，首席科學官
A live webcast of the fireside chat can be accessed on the "Events & Presentations" page in the "Investors" section of the Company's website at . A replay of the webcast will be available for 90 days following the event.
火爐聊天的直播網絡廣播可以在公司網站的"投資者"部分的"事件與演示"頁面上訪問。事件結束後，網絡廣播的重播將在90天內提供。
About Century Therapeutics
關於世紀治療公司
Century Therapeutics (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer and autoimmune diseases that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived cell product candidates are designed to specifically target hematologic and solid tumor cancers, with a broadening application to autoimmune diseases. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer and autoimmune disease care. For more information on Century Therapeutics please visit .
世紀治療公司（納斯達克：IPSC）正在利用成人幹細胞的力量，開發針對癌症和自身免疫疾病的治癒性細胞治療產品，我們相信這將使我們克服第一代細胞治療的侷限。我們的基因工程iPSC衍生細胞產品候選者旨在專門針對血液和實體瘤癌症，同時廣泛應用於自身免疫疾病。我們正在利用我們在細胞重編程、基因工程和製造業-半導體方面的專業知識，開發有潛力克服細胞治療中固有許多挑戰的療法，並提供相對於現有細胞治療技術的顯著優勢。我們相信，我們致力於開發現成的細胞治療將擴大患者的獲取機會，並提供一個無與倫比的機會，推動癌症和自身免疫疾病護理的發展。有關世紀治療公司的更多信息，請訪問。
For More Information:
更多信息：
Investor Relations & Media Contacts
投資者關係與媒體聯繫人
Century Therapeutics
Katja Buhrer
SVP, Head of Corporate Affairs and Strategy
katja.buhrer@centurytx.com
917-969-3438
世紀治療公司
卡佳·布勒
高級副總裁，企業事務與策略負責人
katja.buhrer@centurytx.com
917-969-3438
Argot Partners
Noor Pahlavi
century@argotpartners.com
212-600-1902
阿戈特夥伴
諾爾·帕哈拉維
century@argotpartners.com
212-600-1902
